Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GSK3α/β: A Novel Therapeutic Target for Neuroendocrine Tumors.
Aristizabal Prada ET, Weis C, Orth M, Lauseker M, Spöttl G, Maurer J, Grabowski P, Grossman A, Auernhammer CJ, Nölting S. Aristizabal Prada ET, et al. Among authors: grabowski p. Neuroendocrinology. 2018;106(4):335-351. doi: 10.1159/000481887. Epub 2017 Oct 2. Neuroendocrinology. 2018. PMID: 28968593 Free article.
ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines.
Georgieva I, Koychev D, Wang Y, Holstein J, Hopfenmüller W, Zeitz M, Grabowski P. Georgieva I, et al. Among authors: grabowski p. Neuroendocrinology. 2010;91(2):121-30. doi: 10.1159/000258705. Epub 2009 Nov 14. Neuroendocrinology. 2010. PMID: 19923785
The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S, Rentsch J, Freitag H, Detjen K, Briest F, Möbs M, Weissmann V, Siegmund B, Auernhammer CJ, Aristizabal Prada ET, Lauseker M, Grossman A, Exner S, Fischer C, Grötzinger C, Schrader J, Grabowski P; GERMAN NET-Z study group. Nölting S, et al. Among authors: grabowski p. PLoS One. 2017 Aug 11;12(8):e0182852. doi: 10.1371/journal.pone.0182852. eCollection 2017. PLoS One. 2017. PMID: 28800359 Free PMC article.
Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors.
Briest F, Grass I, Sedding D, Möbs M, Christen F, Benecke J, Fuchs K, Mende S, Kaemmerer D, Sänger J, Kunze A, Geisler C, Freitag H, Lewens F, Worpenberg L, Iwaszkiewicz S, Siegmund B, Walther W, Hummel M, Grabowski P. Briest F, et al. Among authors: grabowski p. Neuroendocrinology. 2018;107(1):1-23. doi: 10.1159/000481506. Epub 2017 Sep 14. Neuroendocrinology. 2018. PMID: 28910819
Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells.
von Hessert-Vaudoncourt C, Lelek S, Geisler C, Hartung T, Bröker V, Briest F, Mochmann L, Jost-Brinkmann F, Sedding D, Benecke J, Freitag H, Wolfshöfer S, Lammert H, Nölting S, Hummel M, Schrader J, Grabowski P. von Hessert-Vaudoncourt C, et al. Among authors: grabowski p. Front Pharmacol. 2024 Feb 5;15:1308686. doi: 10.3389/fphar.2024.1308686. eCollection 2024. Front Pharmacol. 2024. PMID: 38375032 Free PMC article.
FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.
Briest F, Berg E, Grass I, Freitag H, Kaemmerer D, Lewens F, Christen F, Arsenic R, Altendorf-Hofmann A, Kunze A, Sänger J, Knösel T, Siegmund B, Hummel M, Grabowski P. Briest F, et al. Among authors: grabowski p. Oncotarget. 2015 Apr 10;6(10):8185-99. doi: 10.18632/oncotarget.3600. Oncotarget. 2015. PMID: 25797272 Free PMC article.
[Neuroendocrine Neoplasia within the German NET Registry].
Im Namen aller Teilnehmer/innen am Deutschen NET-Registers; Authors; Kollaboratoren:. Im Namen aller Teilnehmer/innen am Deutschen NET-Registers, et al. Z Gastroenterol. 2018 Oct;56(10):1237-1246. doi: 10.1055/a-0661-6099. Epub 2018 Oct 10. Z Gastroenterol. 2018. PMID: 30304748 German.
249 results